Status and phase
Conditions
Treatments
About
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Full description
This is a multicenter, open-label, first-in-human, Phase 1/2 study.
The study will consist of 2 phases:
Each phase of the study will consist of 3 periods:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
106 participants in 2 patient groups
Loading...
Central trial contact
Study Coordinator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal